Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 25, 2023, titled "Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".